SK Discovery Business Model Canvas

The group continuously evaluates and optimizes its portfolio to maximize long-term shareholder value, targeting high-growth sectors like green materials and advanced biotechnology; in 2024 SK Group allocated about KRW 12 trillion to future growth businesses, with SK Inc. reporting a 22% YoY increase in new energy investments. By rebalancing assets and executing targeted divestments—SK hynix sold non-core stakes raising KRW 3.5 trillion in 2023—the subsidiaries stay agile amid global shifts.

SK Discovery runs advanced R&D in life sciences and green materials, targeting eco-friendly copolyesters and novel vaccines; R&D spend hit KRW 210 billion in 2024, up 18% year-over-year, to build tech barriers and secure global margins. Continuous innovation in molecular biology and chemical engineering aims to drive revenue growth toward management’s 2025 target of KRW 1.2 trillion in core businesses.

SK Discovery holds a broad IP portfolio—over 1,200 patents worldwide as of 2025—covering biotech, vaccine platforms, and specialty chemical formulations; these patents block competitors and underpinned KRW 45 billion in licensing revenue in 2024. Continued R&D spending—KRW 220 billion budgeted for 2025—targets new filings to sustain growth in life sciences and green materials.

SK Discovery operates GMP-certified production plants and R&D labs able to run high-precision chemical synthesis and biologics manufacturing; its 2024 capital expenditure on facilities was about KRW 120 billion, supporting batch yields >98% for key compounds. Maintaining these assets ensures compliance with global regulators and reliable delivery of high-performance products to partners and markets.

SK Discovery supplies chemically recycled plastics and bio-based materials that cut CO2 emissions up to 70% versus virgin resin; in 2024 its green portfolio grew 38% to ~200 ktpa, addressing a packaging market seeking 25% recycled content by 2030 and helping B2B clients meet ESG targets while reducing scope 3 exposure and compliance costs.

SK Discovery supplies advanced biologics and vaccine platforms, producing vaccines and blood products that target global threats; in 2024 SK bioscience (related SK group company) reached ~USD 300m vaccine sales and global vaccine capacity scaled to tens of millions of doses, showing SK Discovery’s blend of biotech R&D and large-scale GMP manufacturing secures national vaccine sovereignty and steady revenue streams.

SK Discovery builds multi-year B2B partnerships with industrial clients—50% of 2024 sales came from contracts longer than three years—focusing on joint product development and bespoke supply-chain solutions that cut customer downtime by up to 18%. Maintaining >99% on-time delivery and SLAs tied to service reliability preserves high-value customers and supports repeat revenue representing roughly 60% of EBITDA.

SK Discovery holds quarterly IR sessions and attended 28 investor conferences in 2024, publishing semiannual reports and monthly ESG scorecards; net asset value disclosure increased investor engagement 22% year-over-year. By openly reporting 2024 revenue of KRW 1.8 trillion, a 14% strategic reallocation to bio/pharma, and ESG metrics (Scope 1–2 emissions down 8%), the holding company strengthens long-term shareholder trust.

SK Discovery uses over 30 international sales offices and 120 local distributors to serve 60+ countries, driving roughly 55% of 2024 revenue from overseas markets (about KRW 780 billion of KRW 1.42 trillion total). Local teams speed responses to market requests and regulatory shifts, cutting lead times by ~25% and supporting rapid rollouts of specialty chemicals and pharmaceuticals.

The Korea Exchange (KRX) and digital IR portals like DART and global platforms reach institutional and retail investors; in 2024 KRX average daily trading value was ~KRW 13.5 trillion, so timely earnings, strategy updates, and annual ESG reports (e.g., 2024 Scope 1–3 targets) help sustain liquidity and a fair market cap—proper IR correlates with lower bid-ask spreads and reduced share-price volatility.

This segment covers global industrial manufacturers and automotive firms needing high-performance chemicals and green materials; automotive OEMs alone accounted for about $45 billion in global demand for lightweight polymers in 2024, and SK Discovery targets multi-year supply contracts to meet manufacturers’ decarbonization goals of ~30–50% lifecycle CO2 cuts by 2030.

SK Discovery supplies vaccines, blood products, and contract manufacturing to private pharma firms and national health agencies, addressing a market where global vaccine spending reached about $65B in 2024 and Asia-Pacific healthcare spend grew 6.2% YoY; demand is further driven by aging populations—OECD projects 30%+ over-65 share in several markets by 2030—supporting stable long-term procurement and CMOs revenues.

Construction and maintenance of SK Discovery’s high-tech plants and energy terminals are a major cost, with CAPEX for new hydrogen receiving facilities and chemical-plant circular upgrades estimated at roughly KRW 1.2–1.8 trillion (USD 900M–1.35B) per project and annual maintenance at ~3–5% of CAPEX; these are long-term, upfront investments tied to lifecycle replacement and regulatory compliance.

The primary revenue stream for SK Discovery, as a holding company, is dividend income from profitable subsidiaries; in 2024 SK Gas and SK Chemicals distributed roughly KRW 350 billion and KRW 220 billion respectively, making dividends ~60% of consolidated free cash flow. These payments hinge on units’ market performance—e.g., SK Gas’ 2024 LNG margins and SK Chemicals’ 2024 EBITDA of KRW 1.1 trillion—and fund investments and shareholder returns.

SK Discovery earns steady revenue by licensing the SK brand to subsidiaries and charging centralized management and strategic service fees, which totaled about KRW 120 billion in 2024—roughly 8% of consolidated service revenue—reflecting the group's reputation premium. These fees create predictable cash flow insulated from commodity swings, supporting margin stability during volatile cycles.